Firebrick Pharma Ltd
ASX:FRE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Carbine Resources Ltd
ASX:CRB
|
AU |
|
Kyushu Electric Power Co Inc
OTC:KYSEF
|
JP |
|
Pandox AB
STO:PNDX B
|
SE |
|
Sparebanken Sor
OSE:SOR
|
NO |
Firebrick Pharma Ltd
Other
Firebrick Pharma Ltd
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Firebrick Pharma Ltd
ASX:FRE
|
Other
AU$95.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Other
-AU$186.1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Other
AU$3.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Other
-AU$37k
|
CAGR 3-Years
-164%
|
CAGR 5-Years
49%
|
CAGR 10-Years
-12%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Other
-AU$193.4k
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Other
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Firebrick Pharma Ltd
Glance View
Firebrick Pharma Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is focused to develop Nasodine, a nasal spray that contains the broad spectrum antimicrobial agent called povidone-iodine. The firm is engaged in product formulation, packaging and manufacturing development. Nasodine nasal spray medicine targets the cause of colds, where they start in the nose. Its nasal spray is responsible for respiratory infections, such as the common cold. The firm's Series C funding, Phase III trial has been completed.
See Also
What is Firebrick Pharma Ltd's Other?
Other
95.2k
AUD
Based on the financial report for Jun 30, 2025, Firebrick Pharma Ltd's Other amounts to 95.2k AUD.
What is Firebrick Pharma Ltd's Other growth rate?
Other CAGR 5Y
1%
